Banco Santander’s Neurocrine Biosciences NBIX Stock Holding History

Banco Santander’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,183	Closed	-$310K	–	366
2022 Q2	$310K	Buy	+3,183	New	+$294K	﹤0.01%	350

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Banco Santander's NBIX Position: Q3 2022 in Review

Banco Santander sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 3,183 shares — an estimated $310K sold.

Banco Santander first reported a position in NBIX in Q2 2022 and held it in 1 quarter. The position peaked at $310K in Q2 2022. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

Banco Santander reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
Banco Santander sold 3,183 Neurocrine Biosciences shares in Q3 2022, an estimated $310K.
Banco Santander first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 1 quarter.
Banco Santander's Neurocrine Biosciences position peaked at $310K in Q2 2022.
466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Banco Santander's 13F filing for Q3 2022, filed 8 Nov 2022.